Gamifant

Active Ingredient(s): Emapalumab-lzsg
FDA Approved: * November 20, 2018
Pharm Company: * NOVIMMUNE S.A.
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Gamifant Overview

Emapalumab, marketed under the trade name Gamifant, is an anti-interferon-gamma (IFNγ) antibody used for the treatment of hemophagocytic lymphohistiocytosis (HLH),[3] which currently has no cure.[4] Contents 1 Adverse effects 2 Pharmacology 2.1 Mechanism of action 2.2 Pharmacokinetics 3 Society and culture 4 Research 5 References Adverse effects In the clinical trials that lead to emapalumab's FDA approval, the most commonly reported adverse ef...

Read more Gamifant Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Emapalumab

Recent Gamifant Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Gamifant: (2 results)

Sorted by National Drug Code

• 72171-501 Gamifant 10 mg/2ml Intravenous Injection by Novimmune Sa
• 72171-505 Gamifant 50 mg/10ml Intravenous Injection by Novimmune Sa

Other drugs which contain Emapalumab-lzsg or a similar ingredient: (1 result)

• EMAPALUMAB